StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30215% above fair value
$115.31−4.08 (-3.42%)

Close on Nov 20, 2026Market cap $9.84BP/E –Yield –

Kymera Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Kymera Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$288.89M. For fiscal 2025 it was -$234.34M. The highest annual figure on record is $79.03M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$234.34M–
FY2024Dec 31, 2024-$207.34M–
FY2023Dec 31, 2023-$137.31M–
FY2022Dec 31, 2022-$155.92M–
FY2021Dec 31, 2021-$130.54M-265.2%
FY2020Dec 31, 2020$79.03M+354.9%
FY2019Dec 31, 2019$17.37M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$78.23M–
Q2 FY2026Jun 30, 2026-$54.54M–
Q1 FY2026Mar 31, 2026-$89.27M–
Q4 FY2025Dec 31, 2025-$66.85M–
Q3 FY2025Sep 30, 2025-$27.29M–
Q2 FY2025Jun 30, 2025-$60.58M–
Q1 FY2025Mar 31, 2025-$79.62M–
Q4 FY2024Dec 31, 2024-$62.72M–
Q3 FY2024Sep 30, 2024-$50.00M–
Q2 FY2024Jun 30, 2024-$47.63M–
Q1 FY2024Mar 31, 2024-$46.99M–
Q4 FY2023Dec 31, 2023-$3.58M–
Q3 FY2023Sep 30, 2023-$39.73M–
Q2 FY2023Jun 30, 2023-$46.02M–
Q1 FY2023Mar 31, 2023-$47.98M–
Q4 FY2022Dec 31, 2022-$39.91M–
Q3 FY2022Sep 30, 2022-$35.52M–
Q2 FY2022Jun 30, 2022-$39.72M–
Q1 FY2022Mar 31, 2022-$40.78M–
Q4 FY2021Dec 31, 2021-$38.85M–
Q3 FY2021Sep 30, 2021-$37.57M-129.1%
Q2 FY2021Jun 30, 2021-$31.14M–
Q1 FY2021Mar 31, 2021-$22.99M–
Q4 FY2020Dec 31, 2020-$21.51M–
Q3 FY2020Sep 30, 2020$129.26M–
Q2 FY2020Jun 30, 2020-$15.27M–
Q1 FY2020Mar 31, 2020-$13.45M–
Q4 FY2019Dec 31, 2019-$11.00M–

More Kymera Therapeutics figures

See a number that looks wrong?